Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia

被引：9

作者：

Graveno, Molly E. ^{[1
,4
]}

Carulli, Alison ^{[1
]}

Freyer, Craig W. ^{[1
]}

Mangan, Brendan L. ^{[1
]}

Nietupski, Robert ^{[2
]}

Loren, Alison W. ^{[3
]}

Frey, Noelle, V ^{[3
]}

Porter, David L. ^{[3
]}

Gill, Saar, I ^{[3
]}

Hexner, Elizabeth O. ^{[3
]}

Luger, Selina M. ^{[3
]}

Martin, Mary Ellen ^{[3
]}

McCurdy, Shannon R. ^{[3
]}

Perl, Alexander E. ^{[3
]}

Babushok, Daria, V ^{[3
]}

Pratz, Keith W. ^{[3
]}

机构：

[1] Hosp Univ Penn, Dept Pharm Serv, 3400 Spruce St, Philadelphia, PA 19104 USA

[2] Adventist Hlth, Cent Pharm Serv, Roseville, CA USA

[3] Hosp Univ Penn, Div Hematol Oncol, 3400 Spruce St, Philadelphia, PA 19104 USA

[4] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 07期

关键词：

Relapsed; refractory AML; venetoclax; hypomethylating agent; low-dose cytarabine; SINGLE-CENTER; THERAPY; AML; AZACITIDINE; EXPERIENCE;

D O I：

10.1080/10428194.2022.2042688

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Limited treatment options exist for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Venetoclax (VEN) in combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) has been recently approved for treatment-naive patients unfit for intensive induction. Limited data are available to characterize the efficacy of VEN combinations in R/R AML. We retrospectively analyzed 77 patients with a median of 1 prior therapy (range 0-5) treated with VEN combinations for R/R AML or AML secondary to myelodysplastic syndrome (MDS) progressing after HMA monotherapy. The median overall survival (OS) was 13.1 months (95% CI 9.2-15.1). The median progression-free survival (PFS) was 12 months (95% CI 8.2-15.4) with a median duration of response of 8.9 months (95% CI 5.7-13.9). Overall response rate (ORR) was 68% with a composite complete response (CR) and CR with incomplete hematologic recovery (CRi) rate of 53%. VEN combination therapy is efficacious in R/R AML and further prospective studies are warranted.

引用

页码：1645 / 1650

页数：6

共 50 条

[1] Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Aldoss, Ibrahim
Yang, Dongyun
Aribi, Ahmed
Ali, Haris
Sandhu, Karamjeet
Al Malki, Monzr M.
Mei, Matthew
Salhotra, Amandeep
Khaled, Samer
Nakamura, Ryotaro
Snyder, David
O'Donnell, Margaret
Stein, Anthony S.
Forman, Stephen J.
Marcucci, Guido
Pullarkat, Vinod
[J]. HAEMATOLOGICA, 2018, 103 (09) : E404 - E407
[2] Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
Piccini, Matteo
Pilerci, Sofia
Scappini, Barbara
Mannelli, Francesco
Ciolli, Gaia
Pasquini, Andrea
Fasano, Laura
Quinti, Elisa
Guglielmelli, Paola
Mannarelli, Carmela
Pancani, Fabiana
Zizza, Michela
Signori, Leonardo
Vannucchi, Alessandro M.
Gianfaldoni, Giacomo
[J]. BLOOD, 2022, 140 : 9008 - 9009
[3] Venetoclax with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting
Piccini, Matteo
Pilerci, Sofia
Scappini, Barbara
Bencini, Sara
Peruzzi, Benedetta
Caporale, Roberto
Signori, Leonardo
Fabiana, Pancani
Maria, Vannucchi Alessandro
Gianfaldoni, Giacomo
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S289 - S289
[4] Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
Bewersdorf, Jan Philipp
Giri, Smith
Wang, Rong
Williams, Robert T.
Tallman, Martin S.
Zeidan, Amer M.
Stahl, Maximilian
[J]. HAEMATOLOGICA, 2020, 105 (11) : 2659 - 2663
[5] Venetoclax plus Cladribine plus Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax plus Hypomethylating Agent
Steinauer, Nickolas
McCullough, Kristen
Al-Kali, Aref
Alkhateeb, Hassan
Begna, Kebede
Mangaonkar, Abhishek A.
Saliba, Antoine
Hefazi, Mehrdad
Litzow, Mark R.
Hogan, William J.
Shah, Mithun V.
Pardanani, Animesh D.
Badar, Talha
Murthy, Hemant S.
Foran, James M.
Yi, Cecilia Y. Arana
Tefferi, Ayalew
Gangat, Naseema
[J]. BLOOD, 2023, 142
[6] Venetoclax in Combination with Hypomethylating Agents Compared to Standard Chemotherapy in Relapsed/ Refractory Acute Myeloid Leukemia
Mohassel, Leila
Yakubi, Hanna
Jones, Kendra
Wang, Hongkun
Shafer, Danielle
[J]. BLOOD, 2022, 140 : 6158 - 6159
[7] Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Aldoss, Ibrahim
Yang, Dongyun
Pillai, Raju
Sanchez, James F.
Mei, Matthew
Aribi, Ahmed
Ali, Haris
Sandhu, Karamjeet
Al Malki, Monzr M.
Salhotra, Amandeep
Khaled, Samer
Sun, Weili
O'Donnell, Margaret
Snyder, David
Nakamura, Ryotaro
Stein, Anthony S.
Forman, Stephen J.
Marcucci, Guido
Pullarkat, Vinod
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (10) : E253 - E255
[8] Combination of Venetoclax and Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: Single-Center Clinical Experience
Secilmis, Sema
Bozan, Ersin
Darcin, Tahir
Yaman, Samet
Yigenoglu, Tugcenur
Ulu, Bahar Uncu
Sahin, Derya
Bakirtas, Mehmet
Basci, Semih
Yildiz, Jale
Baysal, Nuran Ahu
Iskender, Dicle
Cakar, Merih Kizil
Sinan, Dal Mehmet
Altuntas, Fevzi
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S192 - S193
[9] Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Ferrara, Felicetto
[J]. BLOOD CANCER JOURNAL, 2020, 10 (01)
[10] Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Felicetto Ferrara
[J]. Blood Cancer Journal, 10

← 1 2 3 4 5 →